MANE surges after Phase 3 trial shows 63% of male patients reported improved hair coverage, boosting FDA approval prospects.
Veradermics (MANE) closed at $101.89 on August 03, 2026, reflecting investor optimism following positive Phase 3 data for its oral hair loss treatment, VDPHL01. The drug demonstrated significant efficacy, with 63% of male patients reporting improved hair coverage compared to 13% on placebo.
The company, with a $4.26 billion market capitalization, awaits additional Phase 3 data for male pattern hair loss and Phase 2 results for female patients in the second half of 2026. If approved, VDPHL01 would be the first FDA-approved oral treatment for pattern hair loss in decades.
MANE’s one-month return stood at -13.05%, though recent clinical advancements have fueled expectations for a potential market disruptor in the $4.26 billion hair loss industry.